share_log

Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60

Benzinga ·  May 8 15:34

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $67 to $60.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment